About Prostate tumor-overexpressed gene 1 protein
Prostate tumor-overexpressed gene 1 protein (PTOV1) is a protein
from Homo sapiens identified by UniProt accession
Q86YD1, 416 residues long.
MolForge cross-references it against 0 known binders and
67 disease associations.
Target properties
| Protein name | Prostate tumor-overexpressed gene 1 protein |
| UniProt accession | Q86YD1 |
| Gene | PTOV1 |
| Organism | Homo sapiens |
| Length | 416 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (67)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.40
- body mass index · score 0.34
- lean body mass · score 0.30
- age at menarche · score 0.15
- fat body mass · score 0.15
- hepatocellular carcinoma · score 0.08
- neoplasm · score 0.08
- non-small cell lung carcinoma · score 0.07
- whole body water mass · score 0.07
- base metabolic rate measurement · score 0.06
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q86YD1-F1 | alphafold | PREDICTED | 67.20 | — |
Amino-acid sequence (416 residues)
MVRPRRAPYR SGAGGPLGGR GRPPRPLVVR AVRSRSWPAS PRGPQPPRIR ARSAPPMEGA RVFGALGPIG PSSPGLTLGG LAVSEHRLSN KLLAWSGVLE WQEKRRPYSD STAKLKRTLP CQAYVNQGEN LETDQWPQKL IMQLIPQQLL TTLGPLFRNS QLAQFHFTNR DCDSLKGLCR IMGNGFAGCM LFPHISPCEV RVLMLLYSSK KKIFMGLIPY DQSGFVSAIR QVITTRKQAV GPGGVNSGPV QIVNNKFLAW SGVMEWQEPR PEPNSRSKRW LPSHVYVNQG EILRTEQWPR KLYMQLIPQQ LLTTLVPLFR NSRLVQFHFT KDLETLKSLC RIMDNGFAGC VHFSYKASCE IRVLMLLYSS EKKIFIGLIP HDQGNFVNGI RRVIANQQQV LQRNLEQEQQ QRGMGG
Explore Prostate tumor-overexpressed gene 1 protein with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets